Omnicell Q1 revenue rises 10% to $270 million; cuts 2025 EBITDA and EPS guidance
Omnicell reported first-quarter 2025 total revenue of $270 million, up 10% from a year earlier, and a GAAP net loss of $7 million, narrower than the $16 million loss a year earlier. The company lowered its full-year 2025 non-GAAP EBITDA and non-GAAP earnings per share guidance, citing higher potential supply chain costs tied to tariffs, which matters to shareholders because the profit outlook is now lower.
Key points
- Q1 2025 total revenue was $270 million, up $24 million or 10% year over year, and above previously issued Q1 guidance.
- Q1 2025 non-GAAP net income was $12 million, or $0.26 per diluted share, compared with $1 million, or $0.03, a year earlier.
- Full-year 2025 non-GAAP EBITDA guidance is now $100 million to $145 million, and non-GAAP EPS guidance is $1.00 to $1.65, both reduced.
- Q1 2025 cash flow from operations was $26 million, compared with $50 million in Q1 2024.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.